TDO as a therapeutic target in brain diseases.

about

Targeting TDO in cancer immunotherapy.Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.Serum kynurenic acid is reduced in affective psychosis.Targeting the Inhibition of Tryptophan 2,3-Dioxygenase (TDO-2) for Cancer Treatment.

P2860

Q38737804-68739475-806D-42FD-9175-66C1FB46DD99 Q39130393-D1947744-A8CC-47C6-BE0F-3BFBDCAD52CF Q41173215-4374FC94-6916-497F-91AE-B9EDAA8B4E04 Q54839145-6B0BAA19-208E-4C56-B2FA-2146FEB121C4

P2860

TDO as a therapeutic target in brain diseases.

Item

http://www.wikidata.org/entity/Q38806660

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

TDO as a therapeutic target in brain diseases.

@en

type

Item

label

TDO as a therapeutic target in brain diseases.

@en

prefLabel

TDO as a therapeutic target in brain diseases.

@en

P1476

TDO as a therapeutic target in brain diseases.

@en

P2093

Cheng-Peng Yu

http://www.w3.org/2001/XMLSchema#string

Da-Ya Luo

http://www.w3.org/2001/XMLSchema#string

Ze-Zheng Pan

http://www.w3.org/2001/XMLSchema#string

P2860

3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims

Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia

Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes.

RNAi-induced silencing of embryonic tryptophan oxygenase in the Pyralid moth, Plodia interpunctella

Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase

Structural and functional analyses of human tryptophan 2,3-dioxygenase

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Sequence of human tryptophan 2,3-dioxygenase (TDO2): presence of a glucocorticoid response-like element composed of a GTT repeat and an intronic CCCCT repeat

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease

P2888

s11011-016-9824-z

P304

737-747

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11011-016-9824-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1003687246

http://www.w3.org/2001/XMLSchema#string

P698

27072164

http://www.w3.org/2001/XMLSchema#string

TDO as a therapeutic target in brain diseases.

about

P2860

P2860

TDO as a therapeutic target in brain diseases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698